This is a short Proactive Investors interview with Coiled Therapeutics executive chairman Dr. Sotirios Stergiopoulos about AO-252 and the value of bringing Professor Ozgur Sahin onto the programme. The core message is that Sahin’s deep TACC3 expertise strengthens scientific credibility, while early clinical data for AO-252 look encouraging: the drug is selective, appears to be acting on relevant cancer pathways, and has shown roughly 30% tumor regression signals without safety issues so far.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
Dr. Sotirios Stergiopoulos argues that Professor Ozgur Sahin’s involvement is a major endorsement of AO-252 because Sahin is described as a world-renowned expert in TACC3 biology and has helped shape the scientific understanding behind the target. Stergiopoulos says the company has worked with him before, that his lab produced important early data, and that his scientific background is especially valuable when selecting which cancer indications to pursue. The second major pillar of the interview is mechanism and early clinical signal. Stergiopoulos explains that AO-252 is not a complete TACC3 inhibitor but a selective protein-protein interaction inhibitor aimed at the C-terminus. He says this approach is intended to interrupt key interactions involved in cancer biology, including effects on the immune system and DNA damage repair. …
Tactically, the stock/story may get near-term support from the Sahin endorsement and the early clinical tumor-regression signal, but the setup remains fragile until more data arrive.
Over the next few months, the market will likely focus on whether AO-252 can sustain efficacy while escalating dose and whether the company can turn early enthusiasm into a broader data package.
Structurally, this is a reminder that in precision oncology, validated biology and credible scientific backing can be as important as capital. If TACC3 proves clinically meaningful, the franchise could have durable strategic value.
Professor Ozgur Sahin’s involvement is a significant endorsement because he is a world-renowned expert in TACC3 biology.
Management says his expertise and prior work on the target validate the scientific basis of the program.
AO-252 is a selective inhibitor using a protein-protein interaction approach around the C-terminus rather than a complete TACC3 inhibitor.
The mechanism is presented as precise and intentionally designed to disrupt cancer-relevant protein interactions.
Early clinical data show close to 30% tumor regression in humans without a safety issue so far.
This is the central bullish efficacy and safety readout in the interview, though still early and incomplete.
Why is Professor Sahin's involvement such a significant endorsement of AO-252?
Professor Ozgur Sahin is a world-renowned scientist in TACC3 biology who put together the work on TACC3 and focused it on oncology. Much of the earlier data came from his lab. Coiled Therapeutics had worked with him previously in defining the role of TACC3 in cancer, and he plays a critical role in the science and in selecting which indications to pursue.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
